KRAS and lung adenocarcinoma: Drug resistance is common in the treatment of molecular-targeted drugs; for example, T790M mutation of EGFR in lung adenocarcinoma was the major cause of gefitinib resistance and other TKI drugs’ resistance [17], while K-Ras mutation was the main cause of cetuximab resistance in colorectal cancer [18].